What is the dosage of Lynparib/Olaparib?

Patients are selected to receive olaparib based on the presence of deleterious or suspected deleteriousHRR gene mutations, including BRCA mutations, or genomic instability based on indication, biomarker and sample type.

1. Recommended dosage: Lynparza is available in the form of tablets. The recommended dosage is 300 mg taken orally twice a day, with or without food. Swallow tablet whole. Do not chew, crush, dissolve, or split tablets. If a patient misses a dose of olaparib, instruct the patient to take the next dose at the scheduled time.

(1) For patients with HRD-positive advanced ovarian cancer, the recommended dose of bevacizumab is 15 mg/kg every three weeks, and the dosing period should be 15 months, including chemotherapy and maintenance periods.

(2) For patients with BRCA mutation-converted mCRPC, the recommended dose of abiraterone is 1,000 mg orally once a day, and abiraterone should be taken orally 5 mg twice a day in combination with prednisone or prednisolone. Patients with mCRPC should also receive concurrent gonadotropin-releasing hormone (GnRH) analog therapy or should undergo bilateral orchiectomy.

2. Medication duration:

(1) Ovarian cancer: Continue treatment until disease progression, unacceptable toxicity, or completion of 2 years of treatment. Patients who achieve complete response (no radiographic evidence of disease) after 2 years should discontinue treatment. Patients with evidence of disease within 2 years may be treated after 2 years if they would derive further benefit from continued treatment.

(2) Breast cancer: Continue treatment for a total of 1 year, or until disease recurrence or unacceptable toxicity, whichever occurs first. According to current clinical practice guidelines, patients receiving olaparib for hormone receptor-positive HER2-negative cancer should continue to receive concomitant endocrine therapy.

(3) Pancreatic cancer, prostate cancer: Continue treatment until disease progression or unacceptable toxicity.

3. Dose adjustment: In order to control adverse reactions, consider interrupting treatment or reducing the dose. It is recommended that the initial dose may be reduced to 250 mg twice daily; if further dose reduction is necessary, reduce to 200 mg twice daily.